A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2009
11/12/2009	CA2723564A1 Sialic acid to support the immune system in the elderly
11/12/2009	CA2723553A1 Solid pharmaceutical formulation with delayed release
11/12/2009	CA2723550A1 Alpha-mercapto-amides
11/12/2009	CA2723545A1 6-pyridin-3-yl-3,4-dihydro-1h-quinolin-2-one derivatives and related compounds as inhibitors of the human aldosterone synthase cyp11b2
11/12/2009	CA2723440A1 Sulfobetaines for therapy
11/12/2009	CA2723434A1 Methods and compositions for oral administration of exenatide
11/12/2009	CA2723431A1 Nip thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
11/12/2009	CA2723403A1 Estrogenic extracts for use in treating vaginal and vulvar atrophy
11/12/2009	CA2723396A1 Benzene sulfonamide thiazole and oxazole compounds
11/12/2009	CA2723372A1 Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
11/12/2009	CA2723307A1 Opioid composition for treating skin lesions
11/12/2009	CA2723302A1 Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
11/12/2009	CA2723237A1 Substituted amides, method of making, and use as btk inhibitors
11/12/2009	CA2723233A1 Specific inhibitors for vascular endothelial growth factor receptors
11/12/2009	CA2723232A1 5-hydroxymethyl-oxazolidin-2-one derivatives for treating bacterial intestinal diseases
11/12/2009	CA2723146A1 Allosteric enhancers of the a1 adenosine receptor
11/12/2009	CA2723144A1 Ophthalmic device, and method of use thereof, for increasing ocular boundary lubrication
11/12/2009	CA2723133A1 Process for production of compound having antagonistic activity on npyy5 receptor, and useful crystal
11/12/2009	CA2723127A1 Inhibitors of protein kinases
11/12/2009	CA2723080A1 Heterocyclic antiviral compounds
11/12/2009	CA2722992A1 Sequential administration of chemotherapeutic agents for treatment of cancer
11/12/2009	CA2722981A1 Selective ligands for the neuronal nicotinic receptors and uses thereof
11/12/2009	CA2722971A1 Sustained release delivery of active agents to treat glaucoma and ocular hypertension
11/12/2009	CA2722944A1 Therapeutic modulation of ocular surface lubrication
11/12/2009	CA2722905A1 Controlled release formulations of alprazolam
11/12/2009	CA2722811A1 Pyrazole compounds as ccr1 antagonists
11/12/2009	CA2722805A1 Trisubstituted pyrazoles as acetylcholine receptor modulators
11/12/2009	CA2722802A1 Granulate comprising escitalopram oxalate
11/12/2009	CA2722776A1 Nmda receptor antagonists for the treatment of neuropsychiatric disorders
11/12/2009	CA2722734A1 3,4-substituted piperidine derivatives as renin inhibitors
11/12/2009	CA2722606A1 Urea compounds as gamma secretase modulators
11/12/2009	CA2722374A1 Method for treating cognitive deficits
11/12/2009	CA2722292A1 1-methylnicotinamide analogs
11/12/2009	CA2721815A1 Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same
11/12/2009	CA2721786A1 Novel class of spiro piperidines for the treatment of neurodegenerative diseases
11/12/2009	CA2721433A1 Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings
11/12/2009	CA2721303A1 Azetidines and cyclobutanes as histamine h3 receptor antagonists
11/12/2009	CA2720493A1 High-fluidity and non-caking pulverulent crystalline maltitol composition
11/12/2009	CA2720133A1 3-hydroxy gepirone for the treatment of attention deficit disorder and sexual dysfunction
11/12/2009	CA2719288A1 Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors
11/12/2009	CA2719234A1 Spiroazaindoles
11/12/2009	CA2717119A1 Compounds that modulate negative-sense, single-stranded rna virus replication and uses thereof
11/12/2009	CA2712586A1 Antibacterial fluoroquinolone analogs
11/11/2009	EP2116616A2 Genes differentially expressed in activated T cells and uses thereof
11/11/2009	EP2116615A1 Hepatocellular carcinoma-related genes and polypeptides, and method for detecting hepatocellular carcinomas
11/11/2009	EP2116602A1 Combination products for treating cancer
11/11/2009	EP2116547A1 Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands
11/11/2009	EP2116546A1 Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands
11/11/2009	EP2116544A2 Spirocyclic cyclohexane derivatives
11/11/2009	EP2116543A1 Novel aminopyrimidine derivative as plk1 inhibitor
11/11/2009	EP2116542A1 Solid of macrolide compound, method for production thereof, and pharmaceutical composition comprising the same
11/11/2009	EP2116541A1 Proline derivatives and their use as dipeptidyl peptidase IV inhibitors
11/11/2009	EP2116540A1 The salts of 4-aniline quinazoline derivative
11/11/2009	EP2116539A1 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
11/11/2009	EP2116538A1 Condensed tetrahydroquinoline derivative and use thereof for medical purposes
11/11/2009	EP2116537A1 Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
11/11/2009	EP2116536A1 Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride
11/11/2009	EP2116535A1 Glucokinase-activating substance
11/11/2009	EP2116533A1 Glucokinase activator
11/11/2009	EP2116532A1 Azapeptide derivatives as HIV protease inhibitors
11/11/2009	EP2116526A1 Derivates of substituted tartaric aicd and usage for preparating beta secretase inhibitors
11/11/2009	EP2116525A1 Process for the preparation of tigecycline in the amorphous form
11/11/2009	EP2116524A1 Method for the synthesis of the sodium salt of retinoyl-cysteic acid and retinoyl-cysteine sulfinic acid
11/11/2009	EP2116523A1 Rexinoid compound having alkoxy group
11/11/2009	EP2116264A1 Preparation for transnasal application
11/11/2009	EP2116262A2 Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
11/11/2009	EP2116256A1 Transdermal immune preparation, method for production of the same, and transdermal immunization method using the same
11/11/2009	EP2116252A1 The use of epimedium flavones and effective components thereof for the preparation of medicaments of promoting proliferations and differentiations of nerve cells
11/11/2009	EP2116250A1 Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
11/11/2009	EP2116249A1 Pharmaceutical compound containing gestagens and/or oestrogens and 5-methyl-(6S)-tetrahydrofolates
11/11/2009	EP2116248A1 Compositions and Methods of Treatment of Cancer
11/11/2009	EP2116247A2 Anti-amnesia compounds and pharmaceutical compositions comprising same
11/11/2009	EP2116246A1 Composition for treatment of pancreatic cancer
11/11/2009	EP2116245A2 EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
11/11/2009	EP2116244A1 Method of treating atherosclerosis, dyslipidemias and related conditions
11/11/2009	EP2116243A1 Gel composition for treating mycosis
11/11/2009	EP2116242A1 New pharmaceutical composition
11/11/2009	EP2116241A1 Pharmaceutical composition
11/11/2009	EP2116240A1 Augmented cognitive training with HT0712
11/11/2009	EP2116239A1 Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
11/11/2009	EP2116238A1 Amino acid composition
11/11/2009	EP2116237A1 Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
11/11/2009	EP2116236A1 Bisbenzamidine derivatives for use as antioxidant
11/11/2009	EP2116235A1 Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
11/11/2009	EP2116234A1 Pharmaceutical composition for external application and adhesive skin patch
11/11/2009	EP2116230A2 Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
11/11/2009	EP2116140A1 Sialic acid to support the immune system in the elderly
11/11/2009	EP2116139A1 Sialic acid to support brain health in the elderly
11/11/2009	EP2115164A2 Method for expression of small antiviral rna molecules with reduced cytotoxicity within a cell
11/11/2009	EP2115140A1 Positively charged water-soluble prodrugs of 1h-imidazo [4, 5-c] quinolin-4-amines and related compounds with very high skin penetration rates
11/11/2009	EP2114982A1 Modulators of hypoxia inducible factor-1 and related uses
11/11/2009	EP2114980A2 Antiviral nucleoside analogs
11/11/2009	EP2114978A1 Organometallic compounds
11/11/2009	EP2114972A2 Monophosphates as mutual prodrugs of muscarinic receptor antagonists and beta-agonists for the treatment of copd and chronic bronchitis
11/11/2009	EP2114971A1 Fused aromatic ptp-1b inhibitors
11/11/2009	EP2114970A1 Tricyclic compounds and their use as glucocorticoid receptor modulators
11/11/2009	EP2114951A2 Novel phosphodiesterase inhibitors
11/11/2009	EP2114948A2 Inhibitors of poly(adp-ribose)polymerase
11/11/2009	EP2114944A2 Tetrahydrobiopterin prodrugs
11/11/2009	EP2114942A1 Novel aminopyrimidine derivatives as plk1 inhibitors

1 ... 2506 2507 2508 2509 2510 2511 2512 2513 2514 2515 2516 2517 2518 2519 2520 2521 2522 2523 2524 2525 2526 ... 7860